A comprehensive guide to multiple sclerosis, discussing: clinical features, diagnosis, disease-modifying therapy, & symptom & medical management written by world-renowned experts in neurology, specifically MS. Dr Cohen and Dr Rae-Grant who are renowned researchers and physicians in the field of MS and are investigators on several key drug trials.

Extensive use of illustrations and succinct format makes this book an easily accessible and key reference guide.

Reviews cutting-edge agents currently in development, while also discussing the clinical features and standard diagnosing criteria and practices of MS from the clinician s perspective

Designed to include thorough descriptions of standard and novel treatment therapies in MS.

Explains how to most effectively use the top therapies in MS in the context of a clinical practice and based on investigational trials.

Concise but comprehensive

Over the past 30 years, there have been significant advances in our understanding of MS due to the use of MRIs to better visualize the disease and due to the introduction of new ameliorating drugs. However, MS is still an incurable disease and diagnosis remains challenging for many physicians; for instance, symptoms often mimic MS, and there is no specific test for the disease. To ensure optimal patient care, there is a need for physicians to remain up to date with new drugs on the market, disease detection, diagnosis, and latest management options.

The Handbook of Multiple Sclerosis provides a concise, easily accessible guide for all healthcare professionals involved in the diagnosis and management of this condition, including standard therapies, as well as more novel treatments. The book will also include comprehensive evaluations of the pharmacological treatments available, including novel investigational agents currently in development.

"

Part of the "What Do I Do Now?" series, Peripheral Nerve and Muscle Disease uses a case-based approach to cover common and important topics in the diagnosis and treatment of neuromuscular disorders. Each chapter provides an overview of the approach to the problem in question followed by a discussion of the diagnosis, key points to remember, and selected references for further reading. In this edition, new cases include: Lambert-Eaton Syndrome, Botulism, Facioscapulohumeral Muscular Dystrophy, and Small Fiber Neuropathy Associated with Fibromyalgia. Peripheral Nerve and Muscle Disease is an engaging collection of thought-provoking cases which clinicians can utilize when they encounter difficult patients on the ward or in the clinic. The volume is also a self-assessment tool that tests the reader's ability to answer the question, "What do I do now?"

This book is a case-based learning guide for neuromuscular diseases. This second volume in the What Do I Do Now? series, Peripheral Nerve and Muscle Disease recreates real clinical situations in which the attending is asked for advice as the neurological consultant. The approach to the clinical question is discussed emphasizing differential diagnosis and treatment pathways. The authors have included clinical pitfalls which they have experienced in their own practice. This is a readable book which can be picked up in spare moments.

Over the past 30 years there have been significant advances in our understanding of multiple sclerosis (MS) due to the use of MRIs to better visualize the disease and because of the introduction of new ameliorating drugs. However, MS is still an incurable disease and diagnosis remains challenging for many physicians; for instance symptoms often mimic MS and there is not a specific test for the disease. To ensure optimal patient care there is a need for physicians to remain up to date with new drugs on the market, disease detection, diagnosis, and latest management options. The Handbook of Multiple Sclerosis (Second Edition) provides a concise, easily assessable guide for all healthcare professionals involved in the diagnosis and management of this condition, including standard therapies, as well as more novel treatments. The book includes comprehensive evaluations of the pharmacological treatments available, including novel investigational agents currently in development.

This book comprehensively reviews the current state of clinical trial methods in multiple sclerosis treatment, providing investigators, sponsors and specialists with current knowledge of outcome measures and study designs for disease and symptom management. The status of the rapidly evolving field of disease-modifying drugs is presented, with emphasis on the most promising therapies currently being tested. Experts discuss disease and symptom management for MS subtypes, including neuromyelitis optica and pediatric MS. In addition, key scientific advances in MS pathology, genetics, immunology and epidemiology are presented. The fourth edition has been extensively revised, featuring more than 50% new material. All chapters have been substantially updated to provide current information on rapidly evolving topics and this volume contains 15 new chapters, reflecting the growth of the field in recent years. This book is an essential reference for practitioners caring for MS patients, investigators planning or conducting clinical trials, and clinical trial sponsors.

Since the publication of the previous edition of this volume, there has been substantial progress in a number of areas of multiple sclerosis (MS) research. Although immunosuppressive treatments continue to be developed and refined, more targeted immunomodulatory therapies are surfacing as we learn more about how the immune system works in health and disease. Multiple Sclerosis Therapeutics, Third Edition provides a comprehensive review of clinical trial methodology and therapeutic modalities in MS. This edition reflects current understanding of the pathophysiology of the disease and includes popular and emerging treatments. Topics include: Biomarkers in MS Pharmacogenomics Emerging therapeutic modalities such as natalizumab, T-cell-based and B-cell-based therapies, cytokine/chemokine-based therapies, statins, and 4-aminopyridine Neuroprotection The use of OCT and MRI to guide disease therapy Within the next several years, we will begin to discover the utility and the limitations of stem cells in the treatment of MS. It is likely that the next edition of this text will include clinical trial data that evaluate early attempts at nervous system regeneration in MS. Until that time occurs, this volume remains an essential resource for neurologists and anyone involved in the treatment of MS.